Brussels, November 3rd 2005 – DNAVision announced today that it will begin service of Roche Diagnostics' AmpliChip™ CYP450 test. The AmpliChip™ CYP450 test has been cleared by the U.S. Food and Drug Administration for diagnostic use. Thanks to genetic information from patients, AmpliChip™ CYP450 test results will help and improve the selection of medications and doses of medications for a wide variety of common conditions such as cardiac diseases, chronic pain, cancer, and common psychiatric disorders.

“DNAVision is proud to be chosen by Roche Diagnostics Belgium as the first European pharmacogenomic private testing laboratory to provide this first FDA approved DNA microarray test” said Dr Arnaud Termonia, scientific advisor of DNAVision. "We are delighted that Roche Diagnostics Belgium has chosen DNAVision for it’s scientific expertise in pharmacogenetic testing and in the use of Affymetrix technology in a high quality environment"

About DNAVision

DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services. DNAVision offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment. DNAVision is a spin-off of BioVallée, University of Brussels and Institute of Pathology and Genetics. More information on DNAVision’s service portfolio can be found on www.dnavision.be

About Roche Diagnostics

Roche Diagnostics Belgium is part of the Roche concern, headquartered in Basel, Switzerland. Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2004 sales by the Pharmaceuticals Division totalled 21.7 billion Swiss francs, while the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 65,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche’s Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our websites www.roche.com and www.roche-diagnostics.com.

Further information:
Jean-Pol Detiffe, DNAVision
Tel. +32 71 378 527
jp.detiffe@dnavision.be
www.dnavision.be